glp 1 effects on inflammation Glucagon-like peptide-1 (GLP-1) has established glycemic GLP-1 Agonists in Cardiovascular Diseases:

Studies indicate positive modifications to gut microbiota in just eight weeks of use, supporting both digestive comfort and microbial diversity

Regulatory, Integrative and Comparative Physiology, vol

Blood glucose monitoring helps identify hypoglycemia or significant fluctuations

As stated in the SmPC, a maintenance dose of 1.7 mg may be considered if patients cannot tolerate the 2.4 mg dose

When exercise was added, these negative effects were largely prevented: exercised rats had higher total bone mineral content, lean mass, and serum IGF-1, and their bone mechanical strength was maintained despite reduced energy availability